Jacqueline R Finger1, Lisa M Kurczewski2, Gretchen M Brophy3. 1. Banner-University Medical Center, Tucson, AZ, USA. jacqueline.finger@bannerhealth.com. 2. Virginia Commonwealth University Health System, Richmond, VA, USA. 3. Department of Pharmacotherapy & Outcomes Science and Neurosurgery, Virginia Commonwealth University, Richmond, VA, USA.
Abstract
BACKGROUND: Currently, a lack of published literature exists regarding the use of clevidipine in the neuroscience population. This agent may be preferred in some patients because of its short half-life, potentially leading to more narrow blood pressure (BP) control in comparison with other agents. The purpose of this study was to compare the difference in time to achieve target systolic blood pressure (SBP) goals with clevidipine versus nicardipine infusions in patients admitted to the neuroscience intensive care unit (NSICU) at our institution. METHODS: A retrospective review was performed on patients receiving clevidipine or nicardipine infusions while in the NSICU between July 1, 2011 and June 30, 2014. Patients were matched based on indication for BP lowering and target SBP. Primary endpoints included time to target SBP and percentage of time within target BP range. RESULTS: Of the 57 patients included in the study, the median time to target SBP was 30 min in the clevidipine group and 46 min in the nicardipine group (p = 0.13). The percentage of time spent within target BP range was 79 versus 78% (p = 0.64). Clevidipine administration resulted in significantly less volume administered per patient versus nicardipine (530 vs. 1254 mL, p = 0.02). CONCLUSIONS: There were no statistically significant differences in acute BP management between the two agents; however, there was a trend toward shorter time to target and significantly less volume administered in the clevidipine group. Either agent should be considered a viable option in a NSICU population.
BACKGROUND: Currently, a lack of published literature exists regarding the use of clevidipine in the neuroscience population. This agent may be preferred in some patients because of its short half-life, potentially leading to more narrow blood pressure (BP) control in comparison with other agents. The purpose of this study was to compare the difference in time to achieve target systolic blood pressure (SBP) goals with clevidipine versus nicardipine infusions in patients admitted to the neuroscience intensive care unit (NSICU) at our institution. METHODS: A retrospective review was performed on patients receiving clevidipine or nicardipine infusions while in the NSICU between July 1, 2011 and June 30, 2014. Patients were matched based on indication for BP lowering and target SBP. Primary endpoints included time to target SBP and percentage of time within target BP range. RESULTS: Of the 57 patients included in the study, the median time to target SBP was 30 min in the clevidipine group and 46 min in the nicardipine group (p = 0.13). The percentage of time spent within target BP range was 79 versus 78% (p = 0.64). Clevidipine administration resulted in significantly less volume administered per patient versus nicardipine (530 vs. 1254 mL, p = 0.02). CONCLUSIONS: There were no statistically significant differences in acute BP management between the two agents; however, there was a trend toward shorter time to target and significantly less volume administered in the clevidipine group. Either agent should be considered a viable option in a NSICU population.
Authors: Adnan I Qureshi; Yuko Y Palesch; Reneé Martin; Jill Novitzke; Salvador Cruz-Flores; As'ad Ehtisham; Mustapha A Ezzeddine; Joshua N Goldstein; Haitham M Hussein; M Fareed K Suri; Nauman Tariq Journal: Arch Neurol Date: 2010-05
Authors: Solomon Aronson; Cornelius M Dyke; Kevin A Stierer; Jerrold H Levy; Albert T Cheung; Philip D Lumb; Dean J Kereiakes; Mark F Newman Journal: Anesth Analg Date: 2008-10 Impact factor: 5.108
Authors: J Claude Hemphill; Steven M Greenberg; Craig S Anderson; Kyra Becker; Bernard R Bendok; Mary Cushman; Gordon L Fung; Joshua N Goldstein; R Loch Macdonald; Pamela H Mitchell; Phillip A Scott; Magdy H Selim; Daniel Woo Journal: Stroke Date: 2015-05-28 Impact factor: 7.914
Authors: Craig S Anderson; Emma Heeley; Yining Huang; Jiguang Wang; Christian Stapf; Candice Delcourt; Richard Lindley; Thompson Robinson; Pablo Lavados; Bruce Neal; Jun Hata; Hisatomi Arima; Mark Parsons; Yuechun Li; Jinchao Wang; Stephane Heritier; Qiang Li; Mark Woodward; R John Simes; Stephen M Davis; John Chalmers Journal: N Engl J Med Date: 2013-05-29 Impact factor: 91.245
Authors: Jerrold H Levy; Miguel Y Mancao; Richard Gitter; Dean J Kereiakes; Alina M Grigore; Solomon Aronson; Mark F Newman Journal: Anesth Analg Date: 2007-10 Impact factor: 5.108
Authors: Edward C Jauch; Jeffrey L Saver; Harold P Adams; Askiel Bruno; J J Buddy Connors; Bart M Demaerschalk; Pooja Khatri; Paul W McMullan; Adnan I Qureshi; Kenneth Rosenfield; Phillip A Scott; Debbie R Summers; David Z Wang; Max Wintermark; Howard Yonas Journal: Stroke Date: 2013-01-31 Impact factor: 7.914
Authors: Charles V Pollack; Joseph Varon; Norman A Garrison; Ramin Ebrahimi; Lala Dunbar; W Frank Peacock Journal: Ann Emerg Med Date: 2008-06-05 Impact factor: 5.721
Authors: Neil Singla; David C Warltier; Sweeta D Gandhi; Philip D Lumb; Robert N Sladen; Solomon Aronson; Mark F Newman; Howard L Corwin Journal: Anesth Analg Date: 2008-07 Impact factor: 5.108
Authors: Brian P Lemkuil; Brian T Gierl; Piyush M Patel; Matthew L Pearn; Liem C Nguyen; Anushirvan Minokadeh; John C Drummond Journal: J Neurosurg Anesthesiol Date: 2016-10 Impact factor: 3.956
Authors: Craig S Anderson; Yining Huang; Ji Guang Wang; Hisatomi Arima; Bruce Neal; Bin Peng; Emma Heeley; Christian Skulina; Mark W Parsons; Jong Sung Kim; Qing Ling Tao; Yue Chun Li; Jian Dong Jiang; Li Wen Tai; Jin Li Zhang; En Xu; Yan Cheng; Stephane Heritier; Lewis B Morgenstern; John Chalmers Journal: Lancet Neurol Date: 2008-04-07 Impact factor: 44.182
Authors: Janelle O Poyant; Philip J Kuper; Kristin C Mara; Ross A Dierkhising; Alejandro A Rabinstein; Eelco F M Wijdicks; Brianne M Ritchie Journal: Neurocrit Care Date: 2019-02 Impact factor: 3.210
Authors: Sara Saldana; James Breslin; Jennifer Hanify; Theodore Heierman; Kristina Larizadeh; Michael Sanchez; William Phipps Journal: Neurocrit Care Date: 2021-12-13 Impact factor: 3.210